Meeting
2014 ASCO Annual Meeting
Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.
Authors
Ruth E Langley
Medical Research Council, Clinical Trials Unit at University College London, London, United Kingdom
Ruth E Langley , Richard H. Wilson , Alistair E. Ring , Howard Gordon Kynaston , David A. Cameron , Christopher Coyle , Duncan Charles Gilbert , Carlo Patrono , Sam Rowley , Claire Murphy , David Adlam , Richard Hubner , Tim Iveson , Robert J Steele , Anne L. Thomas , Timothy J Underwood , Janusz Jankowski , Sudeep Gupta , Conjeevaram S Pramesh , Mahesh Parmar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention/Epidemiology
Track
Cancer Prevention/Epidemiology
Sub Track
Cancer Prevention
Clinical Trial Registration Number
2013-004398-28
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1617)
DOI
10.1200/jco.2014.32.15_suppl.tps1617
Abstract #
TPS1617
Poster Bd #
398A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302).
First Author: Suzanne Cole
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).
First Author: Hiromichi Shirasu
Poster
2020 ASCO Virtual Scientific Program
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.
First Author: Siamak Daneshmand
Poster
2020 Genitourinary Cancers Symposium
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations.
First Author: Sumanta K. Pal